Navigation Links
Scientists uncover strategy able to dramatically reduce chemotherapy's side effects

Researchers in Leuven (VIB/KU Leuven) have confirmed their hypothesis that normalizing blood vessels by blocking oxygen sensor PHD2 would make chemotherapy more effective. They also demonstrated for the first time that this strategy would reduce the harmful side effects of chemotherapy on healthy organs.

Limited success of chemotherapy

The effectiveness of chemotherapy is first and foremost limited by the difficulties of delivering the anticancer drugs to the actual tumor. Tumors are characterized by abnormally shaped blood vessels they are irregular in shape, have weak textures and easily tear. These leaking blood vessels prevent anticancer drugs from reaching tumor cells while promoting metastasis. Secondly, chemotherapy can have seriously harmful effects on healthy organs, leading even to heart and kidney failure.

Oxygen sensor (PHD2)

Earlier research at Max Mazzone's lab had already shown that reduced activity of the oxygen sensor PHD2 under hypoxic conditions resulted in a more streamlined vasculature. In this new study, and using mouse models, Rodrigo Leite de Oliveira, Sofie Deschoemaker and Max Mazzone prove their earlier hypothesis that streamlining blood flow by inhibiting PHD2 can render cancer treatments more effective. Firstly, the better formed blood vessels ensure that the anticancer drugs are distributed throughout the tumor, thus increasing their impact. They also allow for smaller doses a significant advantage when administering toxic drugs. The researchers further proved that inhibiting PHD2 results in the production of anti-oxidant enzymes able to neutralize the harmful side effects of chemotherapy.

A first step toward increasing the effectiveness of chemotherapy

The study is promising: chemotherapy combined with specific PHD2 inhibitors would make chemotherapy more effective while reducing the harmful side effects that place such a heavy burden on patients. Unfortunately, there are no specific PHD2 inhibitors available right now, so we have a long way to go before patients will be able to benefit from this discovery.


Contact: Max Mazzone
VIB (the Flanders Institute for Biotechnology)

Related biology news :

1. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
2. Queens scientists seek vaccine for Pseudomonas infection
3. Scientists produce eye structures from human blood-derived stem cells
4. American Society of Plant Biologists honors early career women scientists
5. Brandeis scientists win prestigious prize for circadian rhythms research
6. Scientists discover new method of proton transfer
7. Salk scientists open new window into how cancers override cellular growth controls
8. - Now Featuring Bespoke Pages for China’s Life Scientists
9. Scientists win $2 million to study new pathway in development and maintenance of lymphoma
10. UGA scientists reveal genetic mutation depicted in van Goghs sunflower paintings
11. Genetic mutation depicted in van Goghs sunflower paintings revealed by scientists
Post Your Comments:
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") ... shareholders, Clean Technology Fund I, LP and Clean Technology ... based venture capital funds which together hold approximately 59% ... diluted, as converted basis), that they have entered into ... holdings in Biorem to TUS Holdings Co. Ltd. ("TUS") ...
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
Breaking Biology Technology: